Hepatic Cell News Volume 6.25 | Jul 15 2022

July 28, 2022

2022-07-15 | HCN 6.25

Hepatic Cell News by STEMCELL Technologies

Vol. 6.25 – 15 July, 2022

TOP
STORY

GCN2 Inhibition Sensitizes Arginine-Deprived Hepatocellular Carcinoma Cells to
Senolytic Treatment

Arginine import was uniquely dependent on the cationic amino acid transporter SLC7A1, whose inhibition slowed HCC cell
growth in vitro and in vivo.
[Cell Metabolism]

Abstract Graphical Abstract

Scientific resources to support your organoids research. Learn More!

PUBLICATIONSRanked by the impact factor of the journal

Context-Specific Roles of Diphthamide Deficiency in Hepatocellular Carcinogenesis

To investigate the impact of diphthamide biosynthesis protein 1 in hepatocellular carcinogenesis, scientists performed
data mining from The Cancer Genome Atlas Liver Hepatocellular Carcinoma dataset.
[Journal of Pathology]

Abstract

Aspirin Modulates Succinylation of PGAM1K99 to Restrict the Glycolysis through NF-κB/HAT1/PGAM1
Signaling in Liver Cancer

Investigators found that aspirin attenuated the phosphoglycerate mutase 1 (PGAM1) succinylation to suppress the PGAM1
enzymatic activities and glycolysis in hepatoma cells.
[Acta Pharmacologica Sinica]

Abstract

Circular Dorsal Ruffles Disturb the Growth Factor-Induced PI3K-Akt Pathway
in Hepatocellular Carcinoma Hep3B Cells

Researchers identified circular dorsal ruffles-expressing cancer cell lines and investigated their cellular
functions.
[Cell Communication and Signaling]

Full Article

Feedback Loop Between Hepatocyte Nuclear Factor 1α and Endoplasmic Reticulum Stress Mitigates Liver
Injury by Downregulating Hepatocyte Apoptosis

Significant apoptosis, hepatocyte nuclear factor alpha upregulation, and nuclear factor kappa B activation were observed
in human-derived hepatocytes during endoplasmic reticulum stress.
[Scientific Reports]

Full Article

Spatiotemporal Expression of HMGB2 Regulates Cell Proliferation and Hepatocyte Size during Liver
Regeneration

In vitro experiments demonstrated that cell proliferation was significantly decreased in high-mobility group box
2 (HMGB2)-knockout hepatocytes.
[Scientific Reports]

Full Article

Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, a
First-in-Class Ketohexokinase Inhibitor for Metabolic Disorders and Non-Alcoholic Fatty Liver Disease

Scientists characterized the transport/metabolic pathways in the hepatic disposition of PF-06835919, a first-in-class
ketohexokinase inhibitor for the treatment of metabolic disorders and non-alcoholic steatohepatitis.
[Drug Metabolism and Disposition]

Abstract

Caffeine Alleviates Acute Liver Injury by Inducing the Expression of NEDD4L and Deceasing
GRP78 Level via Ubiquitination

The authors explored whether or not caffeine’s function was related to glucose-regulated protein 78 (GRP78). Acute liver
injury model was established by lipopolysaccharide (LPS)-treated L02 cells and in vivo administration of LPS/D-galactosamine in mice, then caffeine was pre-treated in L02 cells in mice.
[Inflammation Research]

Abstract

LncRNA XIST Promotes Mitochondrial Dysfunction of Hepatocytes To Aggravate Hepatic
Fibrogenesis via miR-539-3p/ADAMTS5 Axis

Considering the critical role of hepatic stellate cell activation in hepatic fibrosis, scientists revealed the exact role
of x-inactive-specific transcript (XIST) in liver fibrosis and its underlying mechanism.
[Molecular and Cellular Biochemistry]

Abstract

Decursin Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis by Facilitating Ferroptosis of
Hepatic Stellate Cells

Researchers explored the function of decursin on regulating hepatic stellate cells activation and hepatic fibrosis.
[Biochemistry and Cell Biology]

Abstract

REVIEWS

Benign Liver Tumors: Understanding Molecular Physiology to Adapt Clinical Management

Scientists explain the main pathogenic mechanisms of benign liver tumors and how this knowledge could influence clinical
practice.
[Nature Reviews Gastroenterology & Hepatology]

Abstract

Metabolic Mechanisms for and Treatment of NAFLD or NASH Occurring after Liver Transplantation

The authors discuss the putative metabolic mechanisms underlying the emergence of non-alcoholic fatty liver disease
(NAFLD) or non-alcoholic steatohepatitis (NASH) after liver transplantation as well as optimal therapeutic approaches for recipients of liver transplants.
[Nature Reviews Endocrinology]

Abstract

INDUSTRY AND POLICY
NEWS

Inventiva Announces the Screening of the First Patient in LEGEND, a Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Inventiva announced the screening in the US of the first patient in its LEGEND Phase IIa combination trial with
lanifibranor and empagliflozin in patients with non-alcoholic steatohepatitis (NASH) and type 2 diabetes (T2D).
[Inventiva]

Press Release

FEATURED EVENT

Hepatic Cell News Volume 6.25 | Jul 15 2022

GCN2 Inhibition Sensitizes Arginine-Deprived Hepatocellular Carcinoma Cells to
Senolytic Treatment

Context-Specific Roles of Diphthamide Deficiency in Hepatocellular Carcinogenesis

Aspirin Modulates Succinylation of PGAM1K99 to Restrict the Glycolysis through NF-κB/HAT1/PGAM1
Signaling in Liver Cancer

Circular Dorsal Ruffles Disturb the Growth Factor-Induced PI3K-Akt Pathway
in Hepatocellular Carcinoma Hep3B Cells

Feedback Loop Between Hepatocyte Nuclear Factor 1α and Endoplasmic Reticulum Stress Mitigates Liver
Injury by Downregulating Hepatocyte Apoptosis

Spatiotemporal Expression of HMGB2 Regulates Cell Proliferation and Hepatocyte Size during Liver
Regeneration

Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, a
First-in-Class Ketohexokinase Inhibitor for Metabolic Disorders and Non-Alcoholic Fatty Liver Disease

Caffeine Alleviates Acute Liver Injury by Inducing the Expression of NEDD4L and Deceasing
GRP78 Level via Ubiquitination

LncRNA XIST Promotes Mitochondrial Dysfunction of Hepatocytes To Aggravate Hepatic
Fibrogenesis via miR-539-3p/ADAMTS5 Axis

Decursin Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis by Facilitating Ferroptosis of
Hepatic Stellate Cells

Benign Liver Tumors: Understanding Molecular Physiology to Adapt Clinical Management

Metabolic Mechanisms for and Treatment of NAFLD or NASH Occurring after Liver Transplantation

Inventiva Announces the Screening of the First Patient in LEGEND, a Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

3D Cell Culture Symposium

> See All Events

Postdoctoral
Scientist – Liver Metabolism and NAFLD

Associate Professor – Thematic Research
Programs

Research
Technologist – Pediatrics

Postdoctoral
Associate – Lung and Liver Injury in Sickle Cell Disease

Postdoctoral Fellow – Cancer Immunology
& Genomics

> See All Jobs